dm+d

Unassigned

New Medicines

Hypoparathyroidism in adults

Information

New molecular entity
Ascendis Pharma
Ascendis Pharma

Development and Regulatory status

Phase II Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Long-acting prodrug of parathyroid hormone (PTH). In its prodrug inactive form, PTH(1-34) is transiently bound to the TransCon technology which releases unmodified teriparatide, via non-enzymatic hydrolysis of the TransCon linker. Given by subcutanous injection once daily.
This is a rare disorder. The prevalence of hypoparathyroidism is estimated at 37 per 100,000 in the USA and 22 per 100,000 in Denmark. The incidence in Denmark is approximately 0.8 per 100,000 person-years. Estimates of prevalence and incidence of hypoparathyroidism are currently lacking in most other countries [5].
Hypoparathyroidism in adults
Subcutaneous